Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health reported strong growth for 2025 while highlighting its reliance on arbitration-related revenue and a weaker fourth quarter. For the year ended December 31, 2025, total revenue rose to $875.3 million from $479.9 million, driven mainly by the hospital division, which generated $844.2 million. About $527.8 million of hospital revenue, roughly 63%, came from higher acuity claims and success in the Independent Dispute Resolution process, where the company reports prevailing in over 85% of determinations with an average collection rate above 85%.
Full-year net income attributable to Nutex Health increased to $70.8 million, including $117.0 million of non‑cash stock‑based compensation tied to earn‑out shares. Diluted EPS was $10.48. EBITDA attributable to Nutex Health was $168.6 million, and Adjusted EBITDA rose to $259.6 million. Net cash from operating activities totaled $248.1 million. As of year‑end, the company reported total assets of $918.5 million, including cash and cash equivalents of $185.6 million and long‑term debt, net, of $29.2 million.
Fourth quarter 2025 revenue fell to $151.7 million from $257.6 million a year earlier, largely due to a one‑time $55.0 million cumulative true‑up for ineligible arbitration claims and the absence of $69.0 million of arbitration revenue that benefited the prior‑year quarter. Adjusted EBITDA for the quarter declined to $16.6 million. After normalizing for these items, the company states that fourth quarter 2025 revenue would have exceeded the prior‑year period. Hospital division visits grew 11.8% for the full year to 188,279, with a 6.1% increase in the fourth quarter. Nutex also indicated it is launching a second stock repurchase program.
Nutex Health Inc. is a physician-led healthcare company that runs 26 micro-hospitals in 12 states, a population health management arm built around independent physician associations, and a real estate division that owns or consolidates certain hospital properties. It employs 944 full-time staff and works with thousands of physicians.
For the year ended December 31, 2025, hospital division revenue was 844,162 and population health management revenue was 31,095 (both in thousands), for total revenue of 875,257 (in thousands), reflecting rapid growth over 2024 and 2023. The business depends heavily on out-of-network billing and the federal No Surprises Act arbitration process, where Nutex uses a third-party expert to arbitrate disputed claims.
The company plans to open four new hospital facilities in 2026 and launch additional IPAs around its existing micro-hospitals, while acknowledging significant regulatory, reimbursement, arbitration-cost, litigation, and capital needs risks that could affect cash collections, profitability, and future growth.
Pertento Partners LLP and Eduardo Marques filed an amended Schedule 13G reporting passive ownership in Nutex Health, Inc. common stock. As of 12/31/2025, they beneficially owned 324,422 shares, representing 4.6% of the outstanding common stock, with shared voting and dispositive power.
All reported shares are directly owned by advisory clients of Pertento Partners, and no individual client is described as holding more than 5% of the class. The filers state the holdings were not acquired to change or influence control of Nutex Health.
Nutex Health, Inc. director Scott J. Saunders reported receiving an equity award in the form of restricted stock units. On July 14, 2025, he was granted 603 RSUs at a price of $0 per unit, each representing the right to receive one share of Nutex common stock upon vesting.
These RSUs vest 100% on July 14, 2026. If Saunders leaves the company without cause before that vesting date, the award will vest on a pro-rata basis according to the actual time he remained in service with the company.
Nutex Health, Inc. director Michael Lee Reed received an equity grant of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock with $0.001 par value upon vesting, for no cash exercise price.
The 603 RSUs are scheduled to vest 100% on July 14, 2026. If Reed leaves the company without cause before that date, the RSUs will vest on a pro-rata basis according to his actual time in service during the vesting period. After this grant, Reed beneficially owns 603 RSUs directly.
Nutex Health, Inc. director Cheryl Yvonne Grenas reported an equity award in the form of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on July 14, 2026, with a provision that if she leaves the company without cause during the vesting period, the award will vest on a pro-rata basis based on her actual time in service.
Nutex Health director Frank E. Jaumot reported receiving a grant of 603 restricted stock units (RSUs) of Nutex Health, Inc. common stock. The RSUs were granted on July 14, 2025 at an exercise price of $0 and are held directly.
Each RSU represents the right to receive one share of Nutex Health common stock upon vesting. The grant vests 100% on July 14, 2026, with a provision for pro-rata vesting based on time served if Jaumot leaves the company without cause during the vesting period.
Nutex Health Inc. (NUTX) filed a current report to note that its independent auditor, Marcum LLP, has provided formal consent for its audit report to be used in existing registration statements. The consent, filed as Exhibit 23.1, covers Marcum’s report on Nutex Health’s consolidated balance sheet as of December 31, 2023, along with the related consolidated statements of operations, changes in equity and cash flows for the two-year period ended December 31, 2023. That audit report is included in Nutex Health’s Form 10-K/A filed on November 18, 2025. This is a routine step that allows Nutex to continue using its audited financial statements in connection with previously filed registration statements.
Nutex Health Inc. (NUTX) reported that it has released its financial and operating results for the third quarter ended September 30, 2025. The company announced these results on November 19, 2025 and made them available through a press release.
The press release is furnished as Exhibit 99.1 to this current report on Form 8-K, and is designated as furnished rather than filed under securities laws, meaning it is not automatically incorporated into other securities offerings or filings unless expressly stated.
Nutex Health Inc. reported a sharp turnaround for the quarter ended September 30, 2025, with total revenue of $267.8 million versus $78.8 million a year earlier and net income attributable to Nutex of $55.4 million compared with a loss of $8.8 million. The hospital division drove most of the growth, generating $260.2 million in quarterly revenue and $700.5 million for the first nine months, up from $199.4 million in the prior-year period, while population health revenue was stable.
For the first nine months of 2025, total revenue rose to $723.6 million from $222.3 million, and net income attributable to Nutex improved to $59.0 million from a loss of $9.5 million. Basic earnings per share were $8.27 for the quarter and $9.63 year-to-date. Cash and cash equivalents increased to $166.0 million from $40.6 million at December 31, 2024, supported by $177.7 million of net cash from operating activities. Results include substantial non-cash stock-based compensation of $119.6 million year-to-date, largely tied to obligations for under-construction and ramping hospitals, and growing arbitration-related accruals under the No Surprises Act.